老年糖尿病管理建议(2019年ADA指南节选)

2019-01-14 林博 林博讲糖

老年患者是糖尿病的主流人群。但是对于老年糖尿病诊治措施的高质量的临床研究相对较少,从2019年ADA指南可以清楚看到这一点。

老年患者是糖尿病的主流人群。但是对于老年糖尿病诊治措施的高质量的临床研究相对较少,从2019年ADA指南可以清楚看到这一点。

指南提出的对于老年糖尿病管理建议多数基于C级或E级水平的证据,B级证据较少,A级证据没有。本文就其中一些热点问题与重要更新内容简要解读,与诸位同道及糖尿病患者分享。

一、老年糖尿病治疗最关注哪一点?

预防低血糖。永远要把避免老年糖尿病出现低血糖放在第一位来关注。因为相比年轻人,老年人更容易发生低血糖。而且低血糖对老年人的危害程度也远超年轻人。老年患者一次严重的低血糖,可以抵消一年甚至是一辈子降糖带来的益处。

因此,指南把低血糖的预防摆在老年糖尿病管理的首要位置。

二、老年糖尿病血糖控制多少比较合适?

不同老年人身体健康状况差异很大,因此血糖控制水平需要“个体化”。

指南给出老年人血糖、血压、血脂控制目标的详细建议:

1.健康老年人

定义:除糖尿病外,没有其他严重疾病,认知功能正常,体能状态良好。

血糖控制目标:餐前血糖5.0-7.2mmol/L,睡前血糖5.0-8.3mmol/L,HbA1c<7.5%。血压控制目标:<140/90mmHg。血脂控制目标:常规使用他汀。

2.中间状态老年人

定义:合并有多种慢性疾病,日常生活活动受到一定限制,或者有轻到中度的认知功能受损。

血糖控制目标:餐前血糖5.0-8.3mmol/L,睡前血糖5.6-10.0mmol/L,HbA1c<8.0%。血压控制目标:<140/90mmHg。血脂控制目标:常规使用他汀。

3.极差健康状况老年人

定义:出现终末期肾病,或者长期需要他人照护,或者中度度认知功能障碍,或者日常生活活动严重受限。

血糖控制目标:餐前血糖5.6-10.0mmol/L,睡前血糖6.1-11.1mmol/L,HbA1c<8.5%。血压控制目标:<150/90mmHg。血脂控制目标:判断利弊,决定是否使用他汀。

三、老年糖尿病是否以“静养”为宜?

不对。老年人肌肉减少,容易跌倒,而跌倒引起的各种合并症对许多老年人是致命打击。指南推荐老年糖尿病应:适当营养摄入,补充足量优质蛋白。

在保证安全前提下,所有老年糖友都应该进行日常的有氧运动和抗阻训练。

四、老年糖尿病的降糖药使用有哪些注意事项?

安全:首选不引起低血糖的降糖药。适当:避免过度治疗或强化降糖。简化:选择依从性高的简便治疗方案。

具体到各种降糖药的使用,推荐如下。

1.老年糖尿病一线降糖药

仍然是二甲双胍。肾小球滤过率≥30 mL/min/1.73 m2即可安全使用。

2.老年糖尿病二线降糖药

吡格列酮:可安全使用。但对合并有心功能不全与跌倒或骨折风险增加的老年人,需谨慎使用。

DPP4抑制剂:可以安全使用。GLP-1受体激动剂:有血管获益,但可能给老年人带来注射上的不便。

SGLT2抑制剂:可以使用。在成年人糖尿病中已经证实有额外的血管与肾脏保护益处,在老年人中长期应用的安全性证据还在积累。

3.老年糖尿病三线降糖药

胰岛素促泌剂:慎用。如果必须使用,首选短效促泌剂。

4.老年糖尿病胰岛素的应用

注射胰岛素,要求糖尿病患者有较高的自我管理能力。为减少低血糖风险,建议对多数老年糖尿病患者,应首选基础胰岛素,并积极简化胰岛素方案。

(1)基础胰岛素

制定合适的空腹血糖目标。注射时间从睡前调整为上午。每周调整1次胰岛素剂量,每次调整2单位。

(2)餐时胰岛素

如果餐时胰岛素剂量<10单位,尝试停用,改为口服降糖药。如果餐时胰岛素剂量>10单位,尝试减少50%剂量,并加用口服药。

(3)预混胰岛素

放宽血糖控制目标。如果每天2次注射,适当增加早餐前胰岛素量,减少晚餐前胰岛素量。晚餐前的预混胰岛素剂量,如果要增加,应更谨慎,加强睡前与凌晨的血糖监测。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1931706, encodeId=a0f01931e06b8, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Wed Feb 27 16:29:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264679, encodeId=e0cd12646e959, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479536, encodeId=bdda14e9536fd, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358135, encodeId=17ae358135e0, content=是该好好研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:41:47 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042199, encodeId=d4981042199fc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 14 17:29:00 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1931706, encodeId=a0f01931e06b8, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Wed Feb 27 16:29:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264679, encodeId=e0cd12646e959, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479536, encodeId=bdda14e9536fd, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358135, encodeId=17ae358135e0, content=是该好好研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:41:47 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042199, encodeId=d4981042199fc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 14 17:29:00 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-16 般若傻瓜
  3. [GetPortalCommentsPageByObjectIdResponse(id=1931706, encodeId=a0f01931e06b8, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Wed Feb 27 16:29:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264679, encodeId=e0cd12646e959, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479536, encodeId=bdda14e9536fd, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358135, encodeId=17ae358135e0, content=是该好好研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:41:47 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042199, encodeId=d4981042199fc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 14 17:29:00 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1931706, encodeId=a0f01931e06b8, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Wed Feb 27 16:29:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264679, encodeId=e0cd12646e959, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479536, encodeId=bdda14e9536fd, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358135, encodeId=17ae358135e0, content=是该好好研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:41:47 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042199, encodeId=d4981042199fc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 14 17:29:00 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-14 1405898496_61595865

    是该好好研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1931706, encodeId=a0f01931e06b8, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Wed Feb 27 16:29:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264679, encodeId=e0cd12646e959, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479536, encodeId=bdda14e9536fd, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Wed Jan 16 05:29:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358135, encodeId=17ae358135e0, content=是该好好研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Mon Jan 14 18:41:47 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042199, encodeId=d4981042199fc, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 14 17:29:00 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-14 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

老年糖尿病、口干、乏力?这个坑很深!

早上查房,一位住院患者的老伴和孩子们来看望她。聊天中他们的一个孩子突然说:“大夫,我爸昨天到今天觉得浑身没劲,他也有糖尿病,您也给看看吧?”(画外音:为住院患者家属看病也是我们工作的重要部分!这话谁说的?呵呵,是现在的我说的!倘若当时把他放走,我就摊上大事了!!!)

《中国老年糖尿病诊疗措施专家共识(2018版)》解读

近日,中国老年医学学会老年内分泌代谢分会发布《中国老年糖尿病诊疗措施专家共识(2018版)》。为此,我们请该共识编写组组长、解放军总医院田慧教授进行解读。

2017 HKGS/HKSEMR立场声明:老年糖尿病

2017年10月,香港老年科医学会(HKGS)联合香港内分泌,代谢和生殖学会(HKSEMR)共同发布了关于老年糖尿病的立场声明。文章主要针对以下6个方面提出共识,分别为:1.糖尿病管理的个性化因素;2.老年综合征的筛查和评估;3.血糖和血压控制目标;4.药物治疗;5.限制糖尿病饮食;6.家庭管理目标。

Diabetes Obes Metab:初始DPP-4是否增加老年糖尿病患者心血管事件风险?

2017年7月,发表在《Diabetes Obes Metab》的一项由美国科学家进行的研究表明,与替代治疗相比,初始二肽基肽酶-4抑制剂(DPP-4)的老年患者心血管事件风险不增加